Disclosed is a compound represented by formula (I) or a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate thereof. Also disclosed are a preparation method and use of the compound. The compound represented by formula (I) of the present invention is a good AR inhibitor, provides a new option for clinical screening and/or preparation of a drug for treating prostate cancer, and has good application prospects.